光化學洗脫市場報告：趨勢、預測和競爭分析（至 2031 年）

預計全球光交換療法市場在2025年至2031年間的複合年成長率將達到5.7%，其中阻塞性細支氣管炎和復發性急性排斥市場將迎來發展機會。預計全球光交換療法市場在2025年至2031年間的複合年成長率將達到5.7%。該市場的主要促進因素包括自體免疫疾病盛行率的上升、移植物抗宿主疾病病例的增加以及對非侵入性治療方案的需求。

Lucintel 預測體外光化學療法將在預測期內達到最高成長。

根據應用，復發性急性排斥預計將出現高成長。

根據地區，預計亞太地區將在預測期內實現最高成長。

這份超過150頁的綜合報告將為您提供寶貴的見解，協助您的業務決策。以下是一些範例資料和見解：

光化學療法市場的新趨勢

光化學療法市場正在經歷深刻的變革時期，其主要趨勢由技術創新、不斷成長的患者需求和不斷發展的醫療保健系統所推動，有助於重塑全球治療性光化學療法的格局。

• 光交換療法設備的技術進步：更緊湊、自動化且患者友好的光交換療法設備的開發正在改善治療效果。這些進步縮短了治療時間，提高了安全性，並改善了患者的整體體驗。隨著科技的不斷發展，光交換療法有望變得更加便捷和有效率。
• 癌症和自體免疫疾病的治療應用日益廣泛：光化學療法正逐漸被認可為治療膽管細胞淋巴瘤（CTCL）等癌症和移植物抗宿主疾病（GVHD）等自體免疫疾病的有效治療方法。這一趨勢促使全球各地的醫院和診所擴大採用光化學療法，從而改善患者的治療效果並促進市場成長。
• 著重於個人化治療方案：隨著個人化醫療的興起，光交換療法正日益根據個別患者的需求進行客製化，尤其是在癌症治療領域。這一趨勢致力於提高光交換療法的精準度和療效，確保其根據每位患者的獨特病情和治療需求進行量身定做。
• 轉向門診光化學療法：醫院和診所擴大在門診提供光化學療法，為患者提供更便捷的治療。這種轉變得益於光化學療法設備的技術進步，這些設備能夠提高治療效率，減少住院時間和相關費用，並提高患者滿意度。
• 拓展新興市場：由於對先進醫療治療的需求不斷成長，光化學療法市場正在向新興經濟體擴張。印度和中國等國家擴大採用光化學療法治療慢性疾病，為這些地區的市場創造了巨大的成長機會。

這些新興趨勢正在推動技術進步、可及性和治療精準度的提高，從而重塑光化學療法市場。隨著市場的成長，對個人化、高效和門診病人友善的光化學療法選項的需求預計將會增加，尤其是在新興經濟體中，這將促進全球市場的顯著成長。

光化學洗脫市場的最新趨勢

光化學療法市場近期呈現出顯著趨勢，技術、臨床應用和患者照護方面均取得了顯著進展。這些發展推動了光化學療法日益成為各種疾病的有效治療方法，尤其是在癌症和自體免疫疾病的治療方面。

• 美國食品藥物管理局 (FDA)核准新型光化學療法系統美國食品藥物管理局 (FDA) 近期核准了新型光化學療法設備，該設備安全性更高，處理效率更高。這些核准將促進光化學療法的廣泛應用，尤其是在血癌和自體免疫疾病的治療領域，從而進一步擴大市場。
• 光化學療法研究的新興夥伴關係關係：我們注意到，學術機構與醫療保健公司之間正在建立越來越多的策略聯盟，以推進光化學療法研究。這些合作致力於開發更有效、更精準的療法，加速將光化學療法融入標準治療方法。
• 光化學療法在固體癌治療中的應用進展：光化學療法正應用於固體癌的治療，這與它傳統的治療血癌的應用相比，是一個重大轉變。早期臨床試驗已顯示出良好的效果，這可能將光化學療法的應用範圍拓展到更廣泛的癌症治療領域。
• 門診光化學療法的發展：隨著科技的進步，門診光化學療法正變得越來越普遍。可攜式高效設備的開發使患者能夠在門診接受治療，從而提高了便利性並降低了醫療成本。這一趨勢預計將推動光化學療法在全球的普及。
• 光化學療法參與者正在國際上擴張：幾家領先的光化學療法設備製造商正在擴大市場影響，尤其是在亞洲和拉丁美洲。隨著這些地區醫療保健體系的發展，對包括光化學療法在內的先進療法的需求不斷成長，這推動了這些地區的市場成長。

光化學療法市場近期的趨勢是，其應用範圍和有效性不斷提升，尤其是在技術進步、臨床研究和更廣泛的可及性方面。這些變化使光化學療法成為腫瘤學和自體免疫疾病治療的重要選擇，並促進了市場的持續成長和創新。

目錄

第1章執行摘要

第2章全球光化學療法市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球光分離市場趨勢（2019-2024 年）及預測（2025-2031 年）
• 全球光化學療法市場（按類型）
  • 體外光分離療法
  • 白血球分離術
  • 血漿置換
  • 其他
• 全球光化學療法市場（按應用）
  • 阻塞性細支氣管炎症候群
  • 復發性急性排斥反應
  • 其他

第4章。各地區市場趨勢及預測分析（2019-2031）

• 全球光化學療法市場（按地區）
• 北美光化學療法市場
• 歐洲光化學療法市場
• 亞太光化學療法市場
• 世界其他地區的光化學洗脫市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球光化學療法市場成長機會（按類型）
  • 全球光化學洗脫市場的成長機會（按應用）
  • 全球光分離市場各區域成長機會
• 全球光化學療法市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球光化學療法市場容量不斷擴大
  • 全球光化學洗脫市場中的合併、收購與合資企業
  • 認證和許可

第7章主要企業簡介

• Haemonetics
• Fresenius Kabi
• Terumo
• Macopharma
• Mallinckrodt Pharmaceuticals

The future of the global photopheresis market looks promising with opportunities in the bronchiolitis obliterans syndrome and recurrent acute rejection markets. The global photopheresis market is expected to grow with a CAGR of 5.7% from 2025 to 2031. The major drivers for this market are the rising prevalence of autoimmune disease, increasing cases of graft-versus-host disease, and demand for non-invasive treatment options.

Lucintel forecasts that, within the type category, extracorporeal photopheresis is expected to witness the highest growth over the forecast period.

Within the application category, recurrent acute rejection is expected to witness higher growth.

In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Photopheresis Market

The photopheresis market is undergoing significant transformation, with key trends emerging due to innovations in technology, increasing patient demand, and evolving healthcare systems. These trends are helping to reshape the landscape of photopheresis treatment across the world.

• Technological Advancements in Photopheresis Devices: The development of more compact, automated, and patient-friendly photopheresis devices is improving treatment outcomes. These advancements reduce treatment times, increase safety, and enhance the overall patient experience. As the technology continues to evolve, it is expected to make photopheresis more accessible and efficient.
• Growing Adoption for Cancer and Autoimmune Diseases: Photopheresis is being increasingly recognized as an effective treatment for cancers like CTCL and autoimmune diseases such as GVHD. This trend is leading to greater adoption of photopheresis therapies in hospitals and clinics worldwide, improving patient outcomes and expanding market growth.
• Focus on Personalized Treatment Options: With personalized medicine on the rise, photopheresis is being tailored to individual patient needs, particularly in cancer care. This trend focuses on enhancing the precision and efficacy of photopheresis treatments, ensuring that they are suited to each patient's unique condition and treatment requirements.
• Shift toward Outpatient Photopheresis Procedures: Hospitals and clinics are increasingly offering outpatient photopheresis treatments, making it more convenient for patients. This shift is driven by technological advancements in photopheresis devices that enable more efficient treatments, reducing hospital stays and associated costs, and improving patient satisfaction.
• Expansion into Emerging Markets: The photopheresis market is expanding into emerging economies, where there is a growing demand for advanced medical treatments. Countries such as India and China are seeing increased adoption of photopheresis for treating chronic diseases, presenting a significant growth opportunity for the market in these regions.

These emerging trends are reshaping the photopheresis market by driving technological advancements, improving accessibility, and enhancing the precision of treatments. As the market grows, particularly in emerging economies, the demand for personalized, efficient, and outpatient-friendly photopheresis options is expected to increase, contributing to significant growth in the global market.

Recent Developments in the Photopheresis Market

The photopheresis market has seen notable developments in recent years, with significant advancements in technology, clinical applications, and patient care. These developments have contributed to the growing adoption of photopheresis as an effective treatment for a variety of conditions, particularly in the treatment of cancer and autoimmune diseases.

• FDA Approval of New Photopheresis Systems: The U.S. FDA has recently approved new photopheresis devices that offer improved safety features and more efficient processing. These approvals are driving the widespread adoption of photopheresis, particularly in the treatment of blood cancers and autoimmune conditions, which is expanding the market further.
• Emerging Partnerships for Photopheresis Research: There has been an increase in strategic partnerships between academic institutions and healthcare companies to advance photopheresis research. These collaborations are focused on developing more effective and precise treatments, helping to accelerate the integration of photopheresis into standard treatment regimens.
• Development of Photopheresis for Solid Tumors: Photopheresis is being explored for the treatment of solid tumors, a significant shift from its traditional use in blood cancers. Early-stage clinical trials have shown promising results, potentially expanding the use of photopheresis to a broader range of cancer treatments.
• Growth of Photopheresis in Outpatient Clinics: Outpatient photopheresis treatments are becoming more common as technology improves. With the development of more portable and efficient devices, patients can undergo treatment in outpatient settings, improving convenience and reducing healthcare costs. This trend is expected to drive the adoption of photopheresis therapy worldwide.
• International Expansion of Photopheresis Providers: Several leading photopheresis device manufacturers are expanding their market presence in international markets, particularly in Asia and Latin America. As healthcare systems in these regions evolve, there is increased demand for advanced treatments, including photopheresis, which is driving market growth in these areas.

Recent developments in the photopheresis market are enhancing its adoption and effectiveness, particularly through technological advancements, clinical research, and broader accessibility. These changes are positioning photopheresis as a vital treatment option in oncology and autoimmune disease care, contributing to the market's ongoing growth and innovation.

Strategic Growth Opportunities in the Photopheresis Market

The photopheresis market offers several growth opportunities across key applications, particularly in the treatment of cancers, autoimmune disorders, and other chronic conditions. As technology improves and adoption increases, new markets and applications are emerging, offering significant growth potential.

• Cancer Treatment Applications: Photopheresis is increasingly being adopted in the treatment of cancers, especially cutaneous T-cell lymphoma and graft-versus-host disease. The continued development of photopheresis technologies for cancer therapies presents a key growth opportunity, expanding treatment options for patients and increasing market demand.
• Autoimmune Disorder Treatment: Photopheresis has proven effective in treating autoimmune disorders like GVHD and scleroderma. As awareness of its efficacy grows, there is significant potential for expanded use in autoimmune disease management, particularly in regions with high prevalence, such as North America and Europe.
• Pediatric Applications: Photopheresis is gaining traction in pediatric applications for treating autoimmune diseases and certain cancers. As treatment regimens become more personalized and less invasive, photopheresis holds promise in offering children more manageable treatment options with fewer side effects.
• Outpatient Treatment Opportunities: As photopheresis devices become more compact and efficient, the potential for outpatient treatments increases. This development offers a strategic growth opportunity, allowing healthcare providers to offer more flexible and cost-effective treatment options for patients, improving patient satisfaction, and expanding market reach.
• Expanding Markets in Developing Regions: Emerging markets, such as India and China, are increasingly adopting advanced medical technologies like photopheresis. The growing healthcare infrastructure in these regions presents significant growth opportunities for photopheresis providers looking to expand their market presence and serve a growing patient base.

The photopheresis market is poised for substantial growth due to key strategic opportunities in cancer treatment, autoimmune disorders, and pediatric care. As technology advances and accessibility increases, particularly in outpatient settings and emerging markets, these growth areas will drive the market's expansion and enhance its role in global healthcare.

Photopheresis Market Driver and Challenges

The photopheresis market is influenced by various technological, economic, and regulatory drivers and challenges. These factors are shaping the growth of the market by influencing the adoption of photopheresis technology, its effectiveness, and its accessibility across different regions.

The factors responsible for driving the photopheresis market include:

1. Technological Advancements in Photopheresis Devices: The continuous development of more compact, efficient, and automated photopheresis devices is a major driver in the market. These advancements improve patient comfort, reduce treatment times, and increase the overall efficiency of photopheresis therapies, driving greater adoption in clinical settings.

2. Rising Incidence of Autoimmune Diseases and Cancers: An increase in the incidence of autoimmune diseases and cancers, especially hematologic malignancies, is driving the demand for photopheresis treatments. As these conditions become more prevalent, the need for effective treatment options like photopheresis grows, contributing to market expansion.

3. Government Support and Reimbursement Policies: Government initiatives and favorable reimbursement policies are encouraging healthcare providers to adopt photopheresis treatments. This support, especially in developed markets, ensures that photopheresis becomes more accessible to patients, fueling its market growth.

4. Growing Patient Preference for Non-invasive Treatments: Patients increasingly prefer non-invasive treatments like photopheresis over traditional methods such as chemotherapy or surgery. The rising demand for less invasive treatment options is a significant driver for photopheresis adoption, particularly for chronic conditions like autoimmune diseases.

5. Expanding Healthcare Infrastructure in Emerging Markets: Improving healthcare infrastructure in developing regions is opening new opportunities for photopheresis treatment. As hospitals and clinics in these regions invest in advanced technologies, the demand for photopheresis is expected to increase, contributing to market growth.

Challenges in the photopheresis market are:

1. High Treatment Costs: The high cost of photopheresis treatments, including the expense of devices and specialized procedures, remains a significant challenge. These costs can limit the adoption of photopheresis in lower-income regions and may hinder broader market expansion.

2. Efficacy Concerns and Limited Indications: Despite its effectiveness in certain conditions, the efficacy of photopheresis in treating other diseases is still being studied. Limited indications for use in non-cancerous conditions may slow the growth of the market, as more evidence is needed to justify its broader application.

3. Regulatory Hurdles and Approval Delays: The regulatory approval process for new photopheresis devices can be lengthy and complex, delaying market entry. Stringent regulations in different regions may slow the adoption of new technologies, which can impact market growth and innovation.

The major drivers of the photopheresis market include technological advancements, rising disease prevalence, and supportive government policies. However, challenges such as high treatment costs, limited indications, and regulatory hurdles must be overcome for the market to reach its full potential. Addressing these challenges will be key to sustaining growth in the photopheresis market.

List of Photopheresis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies photopheresis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the photopheresis companies profiled in this report include-

• Haemonetics
• Fresenius Kabi
• Terumo
• Macopharma
• Mallinckrodt Pharmaceuticals

Photopheresis Market by Segment

The study includes a forecast for the global photopheresis market by type, application, and region.

Photopheresis Market by Type [Value from 2019 to 2031]:

• Extracorporeal Photopheresis
• Leukapheresis
• Plasmapheresis
• Others

Photopheresis Market by Application [Value from 2019 to 2031]:

• Bronchiolitis Obliterans Syndrome
• Recurrent Acute Rejection
• Others

Photopheresis Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Photopheresis Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. It highlights recent developments by major photopheresis producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the U.S., photopheresis technology is increasingly being used for treating conditions like cutaneous T-cell lymphoma (CTCL) and graft-versus-host disease (GVHD). Key players in the market are focusing on improving the efficiency and safety of photopheresis machines, as well as enhancing patient comfort during treatment.
• China: China is witnessing a surge in demand for photopheresis treatments, particularly for cancer and autoimmune diseases. The government's focus on improving healthcare infrastructure is driving the adoption of photopheresis technologies, and local manufacturers are increasingly involved in the production of photopheresis devices to meet the rising demand.
• Germany: Germany remains at the forefront of photopheresis technology in Europe. Research institutions in the country are developing more advanced systems for photopheresis, particularly targeting hematologic malignancies. The German healthcare system continues to support the integration of photopheresis as a treatment for various blood disorders, pushing forward innovation in the market.
• India: India is seeing rapid adoption of photopheresis in the treatment of conditions like skin diseases and certain types of cancers. Indian hospitals are increasingly investing in photopheresis devices, driven by a growing demand for advanced cancer and autoimmune treatments. This development is enhancing the treatment landscape in the country.
• Japan: In Japan, photopheresis is gaining popularity for treating conditions such as lymphoma and autoimmune disorders. Japan's focus on advancing medical technologies is boosting the market, with local companies developing innovative photopheresis systems that emphasize patient comfort, treatment efficiency, and safety.

Features of the Global Photopheresis Market

Market Size Estimates: Photopheresis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Photopheresis market size by type, application, and region in terms of value ($B).

Regional Analysis: Photopheresis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the photopheresis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the photopheresis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the photopheresis market by type (extracorporeal photopheresis, leukapheresis, plasmapheresis, and others), application (bronchiolitis obliterans syndrome, recurrent acute rejection, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Photopheresis Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Photopheresis Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Photopheresis Market by Type
  • 3.3.1: Extracorporeal Photopheresis
  • 3.3.2: Leukapheresis
  • 3.3.3: Plasmapheresis
  • 3.3.4: Others
• 3.4: Global Photopheresis Market by Application
  • 3.4.1: Bronchiolitis Obliterans Syndrome
  • 3.4.2: Recurrent Acute Rejection
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Photopheresis Market by Region
• 4.2: North American Photopheresis Market
  • 4.2.1: North American Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.2.2: North American Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others
• 4.3: European Photopheresis Market
  • 4.3.1: European Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.3.2: European Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others
• 4.4: APAC Photopheresis Market
  • 4.4.1: APAC Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.4.2: APAC Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others
• 4.5: ROW Photopheresis Market
  • 4.5.1: ROW Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.5.2: ROW Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Photopheresis Market by Type
  • 6.1.2: Growth Opportunities for the Global Photopheresis Market by Application
  • 6.1.3: Growth Opportunities for the Global Photopheresis Market by Region
• 6.2: Emerging Trends in the Global Photopheresis Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Photopheresis Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Photopheresis Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Haemonetics
• 7.2: Fresenius Kabi
• 7.3: Terumo
• 7.4: Macopharma
• 7.5: Mallinckrodt Pharmaceuticals